Avoro Capital Advisors LLC: KRYSTAL BIOTECH (KRYS): Quarterly 13F Position History
As of Q1 2026, Avoro Capital Advisors LLC reported 2,888,888 shares of KRYSTAL BIOTECH (KRYS), worth $746.3M and representing 7.4% of its 13F equity book. The position first appeared in Q4 2021 and has been disclosed across 18 13F-HR filings in Pactolio's tracked window.
- 2,888,888Shares Held (Latest Filing)
- $746.3MReported Market Value (Latest Filing)
- 7.4%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- +$34.0MQuarter-over-Quarter Value Change
- 2,888,888Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 18 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 2,888,888 | 0 | — | $746.3M | 7.4% | $258.3 |
| Q4 2025 | 2,888,888 | +111,111 | +4.0% | $712.2M | 7.0% | $246.5 |
| Q3 2025 | 2,777,777 | +117,777 | +4.4% | $490.4M | 6.3% | $176.5 |
| Q2 2025 | 2,660,000 | 71,000 | -2.6% | $365.6M | 6.4% | $137.5 |
| Q1 2025 | 2,731,000 | +102,178 | +3.9% | $492.4M | 7.7% | $180.3 |
| Q4 2024 | 2,628,822 | +6,600 | +0.3% | $411.8M | 5.8% | $156.7 |
| Q3 2024 | 2,622,222 | +189,222 | +7.8% | $477.3M | 7.0% | $182.0 |
| Q2 2024 | 2,433,000 | 122,555 | -4.8% | $446.8M | 6.0% | $183.6 |
| Q1 2024 | 2,555,555 | 10,000 | -0.4% | $454.7M | 5.3% | $177.9 |
| Q4 2023 | 2,565,555 | 0 | — | $318.3M | 4.4% | $124.1 |
| Q3 2023 | 2,565,555 | +4,744 | +0.2% | $297.6M | 4.6% | $116.0 |
| Q2 2023 | 2,560,811 | +810,811 | +46.3% | $300.6M | 4.1% | $117.4 |
| Q1 2023 | 1,750,000 | +340,000 | +24.1% | $140.1M | 2.1% | $80.1 |
| Q4 2022 | 1,410,000 | +135,000 | +10.6% | $111.7M | 1.7% | $79.2 |
| Q3 2022 | 1,275,000 | +200,000 | +18.6% | $88.9M | 1.6% | $69.7 |
| Q2 2022 | 1,075,000 | +70,000 | +7.0% | $70.6M | 1.4% | $65.7 |
| Q1 2022 | 1,005,000 | +530,000 | +111.6% | $66.9M | 1.2% | $66.5 |
| Q4 2021 | 475,000 | — | — | $33.2M | 0.6% | $69.9 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Avoro Capital Advisors LLC first disclose a KRYS position in 13F-HR filings?
Avoro Capital Advisors LLC first reported KRYSTAL BIOTECH (KRYS) on its 13F-HR filing for the period ending 2021-12-31 (Q4 2021). The position has appeared on 18 reported quarters within Pactolio's tracked window.
What was Avoro Capital Advisors LLC's most recent quarter-over-quarter share-count change in KRYS?
Avoro Capital Advisors LLC held the same 2,888,888 shares of KRYS between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Avoro Capital Advisors LLC's cost basis in KRYS?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.